Reportstack is one of the largest online libraries of market research publications. We are the fastest growing and most preferred provider of business intelligence in the market today. We partner with the world's top publishers and research houses to bring to you expert analysis, accurate data and market information along with the best customer support and user experience. For more details, please visit www.reportstack.com
Tuesday, 30 May 2017
In-Depth Review on Australia Market for Female Urinary Incontinence Slings 2017
Australia Market Report for Female Urinary Incontinence Slings 2017 - MedCore is a new market research publication announced by Reportstack.
General Report Contents• Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends • Market Drivers & Limiters for each chapter segment • Competitive Analysis for each chapter segment • Section on recent mergers & acquisitions The female urinary incontinence sling market includes both synthetic slings and non-synthetic slings. Autologous tissue and allogenic grafts are also available options for slings; however, these treatments are not the focus of this report. The volatility in the market is attributed to ongoing scrutiny by healthcare regulatory agencies such as the FDA in the United States and adverse reactions documented by the Australian Government Department of Health TGA (Therapeutic Goods Administration).
The controversy surrounding urinary incontinence slings predominantly concerns synthetic slings. Due to the negative side effects publicized about slings, however, procedures using both synthetic and biological slings have decreased. The adverse side-effects have resulted in patients and, to a lesser degree, physicians, becoming more cautious about sling procedures. While the repercussions of this controversy will still extend throughout the forecast period, as a result surgeons are giving greater attention to stronger patient consent protocols including full disclaimers of the risks involved.
The negative publicity regarding slings has had the greatest impact in countries without public healthcare. In Australia, there has been a faster response to treat patients with adverse effects with no additional costs for the patient. This has led to fewer lawsuits and complaints regarding the procedure helping to keep the market stable.
Despite the contraction of the urinary incontinence sling market, the number of procedures is still substantial. The number of patients suffering from female urinary incontinence is increasing. The number of patients is also expected to continue increasing throughout the reporting period, as urinary incontinence affects older demographics.
Biological slings procedures have been less adversely affected by the healthcare warnings. This segment comprises a very small portion of the overall market because many believe that collagen based mesh is not as applicable in this indication compared to other areas such as breast reconstruction or hernia repair. There is also a lack of clinical data supporting the use of biologic mesh over synthetic mesh for the treatment of stress incontinence.
Cook Medical Cooper Surgical Vitrolife Boston Scientific Karl Storz Johnson & Johnson Olympus Irvine Scientific Coloplast Kitazato Life Global Richard Wolf Carl Zeiss Rocket Medical Stryker Esco Global Merck KGaA - Genea Biomedx Leica Vitromed Merit Medical Systems Medtronic Astec Bio BTG Hunter Scientific Others include: B-bridge International, Inc., FertiPro, Reproline Medical, Nidacon Medical, Pentax, Hologic, Medgyne, Promis Medical, Ecleris, etc.